Bad Alchemy: Turning Estimates Into Fraud
Client Alert | less than 1 min read | 02.08.06
Building on comments at the Nash & Cibinic Roundtable, David Bodenheimer challenges the oxymoronic trend of government agencies and qui tam whistleblowers to assert defective pricing or false claims based upon second-guessing poor estimates. In his article "'False' or 'Inaccurate' Estimates" published in the December 2005 Briefing Paper (http://www.crowell.com/pdf/Expertise/GovtContracts/BriefingPapers_Bodenheimer.pdf), he explains that estimating -- due to its inherently risky and predictive nature -- requires judgmental forecasts long recognized as appropriate by government pricing guidelines and not suitable for defective pricing and fraud suits complaining about bad estimates of future events.
Insights
Client Alert | 6 min read | 05.12.26
EU Pharma Package: Advertising Compromise Proposal
In our ninth alert in this EU Pharma Package Series, we discussed the proposals of the Commission, Council, and Parliament with respect to advertising of medicinal products.
Client Alert | 6 min read | 05.11.26
FDA’s AI in Early Phase Clinical Trials RFI: An Opportunity to Help Set the Rules of the Road
Client Alert | 4 min read | 05.11.26
New Temporary State Aid Framework Throws A Lifeline To Sectors Hit By The Middle East Crisis
Client Alert | 4 min read | 05.11.26
